Pfizer is a global research-based biopharmaceutical company whose economics depend on discovering, developing, manufacturing and commercializing medicines and vaccines at global scale. In 2025, Pfizer generated $62.6 billion of revenue versus $63.6 billion in 2024. The headline decline masks an important transition: excluding COVID-19 products, revenue grew 6% operationally as Pfizer worked to replace pandemic-era revenue and prepare for future patent expirations.
Industry Problem Pfizer Solves
Healthcare systems face a persistent need for better prevention and treatment of serious disease, but developing a successful medicine requires years of research, clinical trials, regulatory review, manufacturing investment and commercial execution. Most experimental compounds never become approved products. Pfizer absorbs that scientific and financial risk, then attempts to spread the cost of successful innovation across large patient populations and markets.
The business therefore converts scientific knowledge, intellectual property, clinical evidence and regulatory approvals into commercial products. Its scale matters because the company can fund many programs simultaneously while supporting global manufacturing, medical affairs and distribution. For how Pfizer is allocating that scale toward future growth, see our Pfizer Business Strategy 2026.
Pfizer’s Unique Solution
Pfizer combines internal R&D with external business development. Its portfolio spans medicines and vaccines, while acquisitions and licensing expand access to new scientific platforms and assets. The 2025 portfolio included major franchises such as Eliquis and the Prevnar family, which generated approximately $8.0 billion and $6.5 billion respectively.
This model is not simply about having blockbuster drugs. Pfizer must continually replenish its portfolio because product economics change when patents expire, competitors enter, clinical results disappoint or reimbursement conditions tighten. The company therefore manages a pipeline of current products, lifecycle extensions, new indications and new molecular assets.
The principal vulnerabilities of this model are covered in our Pfizer SWOT Analysis 2026.
Pfizer Business Model
Patented medicines and vaccines
Most Pfizer revenue comes from manufacturing and selling biopharmaceutical products. Patent protection and regulatory exclusivity can give successful products a period of differentiated economics, allowing Pfizer to recover substantial R&D and commercialization costs. The value of a franchise depends on clinical differentiation, addressable patient population, access, pricing, duration of exclusivity and competitive intensity.
Portfolio diversification
Pfizer operates across multiple therapeutic areas and product categories. Diversification matters because individual medicines can face abrupt changes from trial outcomes, safety findings, reimbursement decisions or generic and biosimilar competition. A broad portfolio reduces—but does not eliminate—the economic dependence on individual assets.
Business development as an innovation engine
Pfizer supplements internal discovery through acquisitions, collaborations and licensing. In 2025, the company completed the acquisition of Metsera and entered licensing agreements including transactions with 3SBio and YaoPharma. These moves illustrate a capital-allocation model in which Pfizer can buy or license promising science rather than relying exclusively on its own laboratories.
Global manufacturing and commercial infrastructure
Once a product succeeds clinically and wins approval, Pfizer can use its manufacturing and commercial network to scale it across markets. This infrastructure is a competitive asset because pharmaceutical value is realized only when approved science becomes reliably supplied medicine with reimbursement and physician adoption.
The external forces influencing those economics are examined in our Pfizer PESTEL Analysis 2026.
How Does Pfizer Make Money?
Pfizer primarily earns revenue from product sales to wholesalers, retailers, hospitals, clinics, government agencies and other healthcare channels. The economic engine begins with R&D but monetization occurs when medicines and vaccines are prescribed, administered and reimbursed.
Eliquis was Pfizer’s largest medicine in 2025 at about $7.96 billion of revenue, or roughly 13% of company revenue. The Prevnar family generated about $6.49 billion, around 10%. This illustrates both the power and risk of blockbuster economics: a relatively small number of products can account for a meaningful share of sales.
COVID-19 products remain part of the portfolio but are no longer the central growth engine. Pfizer reported that excluding COVID-19 products, 2025 revenue grew 6% operationally. Strategically, that is important because it shows the underlying portfolio expanding even while total reported revenue declined.
Pfizer Financial Analysis
2025 revenue of $62.6 billion was about $1.0 billion below 2024’s $63.6 billion. However, Pfizer emphasized improved productivity and margins from simplifying and streamlining the organization. The financial story is therefore less about maximizing near-term revenue and more about resetting the cost base while redirecting investment toward future growth.
Pfizer’s scale allows substantial R&D investment, but scale also raises the hurdle for pipeline replacement. A small biotechnology company can transform its growth profile with one successful drug; Pfizer must generate several multibillion-dollar franchises over time to offset losses of exclusivity across a very large revenue base.
The product mix matters as much as the top line. Eliquis and Prevnar together generated more than $14 billion, demonstrating significant franchise concentration. Strong commercial execution can extend franchise value through market penetration and new indications, but patent expiry eventually changes the economics.
Cost discipline is therefore strategically linked to portfolio renewal. Savings from organizational simplification and manufacturing optimization can create capacity to fund R&D and business development without requiring equivalent revenue growth in the near term.
Future of Pfizer’s Business Model
Pfizer’s future depends on replacing mature-product and COVID-era revenue with a new generation of medicines. Management entered 2026 with a sharpened R&D pipeline and an explicit focus on areas where it believes Pfizer’s science and capabilities can create differentiated value.
Oncology is particularly important following the Seagen acquisition, while 2025 business-development moves expanded Pfizer’s exposure to obesity and other growth areas. These investments shift the model toward therapeutic categories with large unmet need and potentially substantial commercial markets.
Digital technology and AI may also change R&D productivity. Pfizer said it plans to expand to more than 1,200 GPUs over two years to support growing AI demand. The strategic value will depend on whether computational investment shortens discovery cycles, improves clinical-development decisions or raises organizational productivity.
Ultimately, Pfizer’s business model is a portfolio-renewal machine. Cash generated by current medicines funds science and acquisitions; successful pipeline assets become protected commercial franchises; those franchises finance the next generation. The model creates enormous value when scientific productivity and capital allocation are strong, but it requires continual renewal because every blockbuster has a finite economic life.
Source: Pfizer, 2025 Form 10-K.